## Bianca Schulte

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7705954/publications.pdf

Version: 2024-02-01

687363 752698 20 900 13 20 citations h-index g-index papers 23 23 23 1637 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Correlation between a quantitative antiâ€SARSâ€CoVâ€2 IgG ELISA and neutralization activity. Journal of Medical Virology, 2022, 94, 388-392.	5.0	89
2	Andrographolide Derivatives Target the KEAP1/NRF2 Axis and Possess Potent Antiâ€SARSâ€CoVâ€2 Activity. ChemMedChem, 2022, 17, e202100732.	3.2	6
3	Dynamics, outcomes and prerequisites of the first SARS-CoV-2 superspreading event in Germany in February 2020: a cross-sectional epidemiological study. BMJ Open, 2022, 12, e059809.	1.9	7
4	SARS-CoV-2 in Environmental Samples of Quarantined Households. Viruses, 2022, 14, 1075.	3.3	30
5	Persistent Maintenance of Intermediate Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response. Journal of Virology, 2022, 96, .	3.4	11
6	Detectable SARS-CoV-2 RNAemia in Critically III Patients, but Not in Mild and Asymptomatic Infections. Transfusion Medicine and Hemotherapy, 2021, 48, 154-160.	1.6	4
7	Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4+ TÂcell help. Cell Reports, 2021, 35, 109320.	6.4	47
8	Case Report: Infection With SARS-CoV-2 in the Presence of High Levels of Vaccine-Induced Neutralizing Antibody Responses. Frontiers in Medicine, 2021, 8, 704719.	2.6	8
9	Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany. Nature Communications, 2020, 11, 5829.	12.8	207
10	Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals. Infectious Diseases and Therapy, 2020, 9, 837-849.	4.0	34
11	Novel monoclonal antibodies to the SERINC5 HIV-1 restriction factor detect endogenous and virion-associated SERINC5. MAbs, 2020, 12, 1802187.	5.2	3
12	Characteristic Temporary Loss of Taste and Olfactory Senses in SARS-CoV-2-positive-Individuals with Mild Symptoms. Pathogens and Immunity, 2020, 5, 117.	3.1	16
13	Localization to detergent-resistant membranes and HIV-1 core entry inhibition correlate with HIV-1 restriction by SERINC5. Virology, 2018, 515, 52-65.	2.4	47
14	Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans. Journal of Virology, 2018, 92, .	3.4	7
15	MxB Is Not Responsible for the Blocking of HIV-1 Infection Observed in Alpha Interferon-Treated Cells. Journal of Virology, 2016, 90, 3056-3064.	3.4	21
16	Restriction of HIV-1 Requires the N-Terminal Region of MxB as a Capsid-Binding Motif but Not as a Nuclear Localization Signal. Journal of Virology, 2015, 89, 8599-8610.	3.4	59
17	Contribution of MxB Oligomerization to HIV-1 Capsid Binding and Restriction. Journal of Virology, 2015, 89, 3285-3294.	3.4	49
18	HIV-1 capsids bind and exploit the kinesin-1 adaptor FEZ1 for inward movement to the nucleus. Nature Communications, 2015, 6, 6660.	12.8	102

#	Article	IF	CITATIONS
19	MxB binds to the HIV-1 core and prevents the uncoating process of HIV-1. Retrovirology, 2014, 11, 68.	2.0	134
20	A Reducing Milieu Renders Cofilin Insensitive to Phosphatidylinositol 4,5-Bisphosphate (PIP2) Inhibition. Journal of Biological Chemistry, 2013, 288, 29430-29439.	3.4	15